Announcement About Convening of the Extraordinary General Meeting of Shareholders of Joint Stock Company Olainfarm
Management Board of the Joint Stock Company Olainfarm, unitary registration number: 40003007246, registered address: Rupnicu iela 5, Olaine, LV-2114, announces that on March 22nd, 2021, request to convene an extraordinary general meeting of shareholders with following agenda - 1) Internal auditing of JSC Olainfarm; 2) Other issues, has been received from shareholder OLFIM OÜ, registration number: 14601045, registered address: Harju maakond, Kuusalu vald, Pudisoo küla, Männimäe, 74626, Estonia, representing 7.79% of the share capital of Joint Stock Company Olainfarm.
Management Board of Joint Stock Company Olainfarm based on the shareholder s request hereby convenes and announces that Extraordinary General Meeting of shareholders of Joint Stock Company Olainfarm will be held on June 18
Olainfarm: Recording of the Fourth Quarter 2020 Investor Conference Webinar
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Olainfarm invites to Fourth Quarter 2020 Investor Conference Webinar
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Olainfarm: Information expressed in the public domain by the Repharm Group is deceptive and contradictory
Today, on February 19, information has arrived in the public domain that the company from Repharm Group will acquire the shares of JSC Olainfarm directly and indirectly owned by Anna Emilija Maligina.
The Chairman of the Management Board of JSC Olainfarm Jeroen Weites points out that Signe Baldere - Sildedze, the legal representative of Anna Emilija Maligina, has informed the Board of JSC Olainfarm that the information in the public domain is false and the deal entered with SIA Farma Fund (previous name Zdorovie Europe) is not valid. Consequently, there is no basis for Repharm group to make such a statement.